1910 Genetics focuses on improving drug discovery by combining artificial intelligence with biological research. Their technology helps identify and develop treatments for diseases that are hard to treat using traditional methods, specifically targeting "undruggable" parts of the human proteome. The company works with pharmaceutical firms, research institutions, and healthcare providers to create both small molecule drugs and protein therapeutics more efficiently. Unlike many competitors, 1910 Genetics offers a complete platform that covers the entire early drug discovery process, from target identification to treatment design. Their goal is to find effective therapies for challenging medical conditions, supported by partnerships and grants, including funding from the National Institutes of Health for non-opioid chronic pain treatments.

Playground Global

Tuck Lye Koh

Emles Advisors

Scientia Ventures

Sam Altman

Y Combinator

FoundersX Ventures

National Institutes of Health

AI & Machine Learning

Biotechnology

1910 Genetics

BOSTON--(BUSINESS WIRE)--1910 Genetics (or “1910”), the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, today announced a new five-year commercial agreement and go-to-market collaboration with Microsoft to harness advanced artificial intelligence (AI) and next-generation, high-performance computing (HPC) to reverse 70 years of declining pharmaceutical RD productivity. 1910 will combine its massive computational and wet lab biological data, robotics-driven laboratory automation and multimodal AI models for drug discovery with Microsoft’s HPC platform, Azure Quantum Elements, empowering researchers worldwide with a groundbreaking cloud platform purpose-built at the intersection of AI and HPC to accelerate scientific discovery. 1910 will offer the platform to pharmaceutical, biotechnology, government, academic, and research institutions via three partnership models: Co-discovery, Co-engineering, and Platform-as-a-Service. Potential partners can sign up here for early access

Microsoft And 1910 Genetics Partner To Build The Infrastructure Layer For Drug Discovery And Development Using Ai And High-Performance Computing

BOSTON--(BUSINESS WIRE)--1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to accelerate the design of small molecule and protein therapeutics, today announced that it has appointed Patrick Genestin as Chief Business Officer. Genestin will lead strategic business development partnerships with biotech and pharmaceutical companies to leverage 1910’s AI-driven drug discovery platforms across all stages of preclinical drug discovery and in all major therapeutic areas. Genestin brings more than 25 years of pharmaceutical business development experience in leading collaborations ranging from licensing, co-development, and co-commercialization, to mergers and acquisitions

1910 Genetics Appoints Patrick Genestin As Chief Business Officer

1910 Genetics launches CANDID-CNS(TM), an AI model for blood-brain Barrier Permeability prediction that outperforms the industry standard.

1910 Genetics Launches CANDID-CNS(TM), an AI Model for Blood-Brain Barrier Permeability Prediction that Outperforms the Industry Standard

1910 Genetics appoints Bridget Cole to Chief Scientific Officer.

1910 Genetics Appoints Bridget Cole to Chief Scientific Officer

1910 Genetics appoints Dr. Shaan C. Gandhi as independent board director.

1910 Genetics Appoints Dr. Shaan C. Gandhi as Independent Board Director

Accenture (NYSE: ACN) has invested, through Accenture Ventures, in 1910 Genetics (or “1910”), a biotechnology company advancing small and large molecu

Accenture Collaborates with 1910 Genetics to Help Biopharma Companies Transform Drug Discovery with AI

BOSTON--(BUSINESS WIRE)--1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, today announced that it has appointed Desney Tan, Vice President and Managing Director of Microsoft Health Futures, to the company’s Board of Directors. With experience in artificial intelligence, machine learning and genomics, Tan brings the board a unique perspective on the benefits and opportunities of combining biomedical technologies with life sciences. “It is rare to find a board member who has direct experience and success in bringing together biomedical technologies, such as artificial intelligence and machine learning, with life sciences to help solve healthcare’s biggest issues,” said Jen Nwankwo, Ph.D., 1910 Genetics’ Founder and Chief Executive Officer. “Desney’s experience, not only with Microsoft, but with advising startups and as an angel investor, brings an indispensable viewpoint to our board and the extended team. I am looking forward to the breadth of experience he is bringing to our board.”

1910 Genetics Appoints Desney Tan From Microsoft To Board Of Directors

Accenture is investing in 1910 Genetics' AI platform, ITO, which integrates lab and computer simulations to accelerate drug development. This collaboration aims to reduce time and costs, enhancing access to new treatments for patients, including in the Netherlands. 1910 Genetics joins Accenture Ventures' Project Spotlight, benefiting from Accenture's expertise and network to scale innovations. This investment supports faster medical breakthroughs for patients.

Accenture Invests in 1910 Genetics' AI Platform

1910 Genetics Appoints Desney Tan From Microsoft To Board Of Directors | Business Wire

1910 Genetics launches advanced AI model for blood-brain barrier drug permeability.

1910 Genetics Launches Advanced AI Model for Blood-Brain Barrier Drug Permeability

“Patrick Genestin is an extremely accomplished, passionate, and respected business leader with a penchant for establishing strategic partnerships, attracting new investment, and stimulating growth,” said Slone Partners CEO Leslie Loveless. Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Patrick Genestin as Chief Business Officer at 1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation, and biological automation to accelerate the design of small molecule and protein therapeutics

Slone Partners Places Patrick Genestin As Chief Business Officer At 19

AI-driven drug discovery for challenging diseases

1910 Genetics

AI-driven drug discovery for challenging diseases

1910 Genetics

AI-driven drug discovery for challenging diseases

About

Simplify's Take

What believers are saying

What critics are saying

What makes 1910 Genetics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

There are no jobs for 1910 Genetics right now.